Diabetes Core Update Podcasts
Diabetes Core Update is a monthly audio podcast devoted to
presenting and discussing the latest clinically relevant articles
from ADA’s four scholarly journals—
Diabetes, Diabetes Care, Clinical Diabetes, and
Diabetes Spectrum—as well as notable articles from other journals related to diabetes research and care. Each episode is approximately 30 minutes long and includes discussion of 4–6 recently published articles and interviews with authors. Intended for the busy health
care professional Diabetes Core Update examines how the latest research
and information published in ADA journals and beyond are relevant to
clinical practice and can be applied in a treatment setting.
For more information about each of ADA’s science and medical journals, please visit diabetesjournals.org.
Presented by:
Neil Skolnik, M.D. , Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health
Listen and follow Diabetes Core Update
Apple Podcasts | Amazon Music | Spotify | 
January 7, 2025
Diabetes Core Update January 2025
Play Episode
Total Time: 41:56 | File Size: 58 MB
Sources
Results From a Randomized Trial of Intensive Glucose Management Using CGM Versus Usual Care in Hospitalized Adults With Type 2 Diabetes: The TIGHT Study. Hirsch et al. Diabetes Care 2025;48(1):118-124. https://doi.org/10.2337/dc24-1779.
Tirzepatide for Obesity Treatment and Diabetes Prevention. Jastreboff et al. N Engl J Med 2024;Epub ahead of print. https://doi.org/10.1056/nejmoa2410819.
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes. Bi et al. N Engl J Med 2024;Epub ahead of print. https://doi.org/10.1056/nejmoa2412006.
Association of Insulin Resistance With Radiographic Lung Abnormalities and Incident Lung Disease: The Framingham Offspring Study. Raju et al. Diabetes Care 2025;48(1):143-148. https://doi.org/10.2337/dc24-1754.
Life Course Associations Between Ambient Fine Particulate Matter and the Prevalence of Prediabetes and Diabetes: A Longitudinal Cohort Study in Taiwan and Hong Kong. Yi et al. Diabetes Care 2025;48(1):93-100. https://doi.org/10.2337/dc24-1041.
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. Bliddal et al. N Engl J Med 2024;391(17):1573-1583. https://doi.org/10.1056/nejmoa2403664.
December 5, 2024
Diabetes Core Update December 2024
Play Episode
Total Time: 34:39 | File Size: 48 MB
Sources
Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Wang et al. Alzheimers Dement 2024;Epub ahead of print. https://doi.org/10.1002/alz.14313.
Increasing Medication Use and Polypharmacy in Type 2 Diabetes: The Danish Experience From 2000 to 2020. Johansson et al. Diabetes Care 2024;47(12):2120-2127. https://doi.org/10.2337/dc24-0011.
Association of Energy Intake and Dietary Glycemic Load in Different Time Periods With Cardiovascular Disease Mortality Among U.S. Adults With Type 2 Diabetes. Dai et al. Diabetes Care 2024;47(12):2172-2179. https://doi.org/10.2337/dc24-1345.
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studies. McCormick et al. BMJ 2024;30;387:e080035. https://doi.org/10.1136/bmj-2024-080035.
GLP-1 Receptor Agonists and the Path to Sustainable Obesity Care. Manne-Goehler et al. JAMA Intern Med 2024;Epub ahead of print. https://doi.org/10.1001/jamainternmed.2024.3579.
November 5, 2024
Diabetes Core Update November 2024
Play Episode
Total Time: 36:02 | File Size: 50 MB
Sources
Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment. Wysham et al. N Engl J Med 2024;Epub ahead of print. https://doi.org/10.1056/nejmoa2403953.
Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder. Wang et al. JAMA Netw Open 2024;7(9):e2435247. https://doi.org/10.1001/jamanetworkopen.2024.35247.
Associations of Diabetes and Prediabetes With Mortality and Life Expectancy in China: A National Study. Tian et al. Diabetes Care 2024;47(11):1969-1977. https://doi.org/10.2337/dca24-0012.
GLP-1 Medication Use for Type 2 Diabetes Has Soared. Hegland et al. JAMA 2024;332(12):952-953. https://doi.org/10.1001/jama.2024.18219.
Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes. Htoo et al. Diabetes Care 2024;47(11):1900-1907. https://doi.org/10.2337/dc24-0270.
October 2, 2024
Diabetes Core Update October 2024
Play Episode
Total Time: 37:33 | File Size: 52 MB
Sources
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. Solomon et al. N Engl J Med 2024;Epub ahead of print. https://doi.org/10.1056/nejmoa2407107.
Comprehensive Multiple Risk Factor Control in Type 2 Diabetes to Mitigate Heart Failure Risk: Insights From a Prospective Cohort Study. Huang et al. Diabetes Care 2024;47(10):1818-1825. https://doi.org/10.2337/dc24-0864.
Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. McGowan et al. Lancet Diabetes Endocrinol 2024;12(9):631-642. https://doi.org/10.1016/s2213-8587(24)00182-7.
Diabetes, Prediabetes, and Brain Aging: The Role of Healthy Lifestyle. Dove et al. Diabetes Care 2024;47(10):1794-1802. https://doi.org/10.2337/dc24-0860.
Sitting Time and Its Interaction With Physical Activity in Relation to All-Cause and Heart Disease Mortality in U.S. Adults With Diabetes. Dai et al. Diabetes Care 2024;47(10):1764-1768. https://doi.org/10.2337/dc24-0673.
August 28, 2024
Diabetes Core Update September 2024
Play Episode
Total Time: 23:53 | File Size: 33 MB
Sources
Age of Diabetes Diagnosis and Lifetime Risk of Dementia: The Atherosclerosis Risk in Communities (ARIC) Study. Hu et al. Diabetes Care 2024;47(9):1576–1583. https://doi.org/10.2337/dc24-0203.
Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes. Wang et al. JAMA Netw Open 2024;7(7):e2421305. https://doi.org/10.1001/jamanetworkopen.2024.21305.
Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data. Wang et al. Ann Intern Med 2024;177(8):1016-1027. https://doi.org/10.7326/m23-2718.
Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Liu et al. Lancet 2024;20;404(10449):245-255. https://doi.org/10.1016/s0140-6736(24)01028-6.
Long-term Neurobehavioral and Metabolic Outcomes in Offspring of Mothers With Diabetes During Pregnancy: A Large, Population-Based Cohort Study in Ontario, Canada. Feig et al. Diabetes Care 2024;47(9):1568-1575. https://doi.org/10.2337/dc24-0108.
July 30, 2024
Diabetes Core Update August 2024
Play Episode
Total Time: 35:10 | File Size: 51 MB
Sources
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. Perkovi et al. N Engl J Med 2024(2):109-121. DOI: 10.1056/NEJMoa2403347.
Association Between Microvascular Disease and Cardiorespiratory Fitness Among Adults With Type 2 Diabetes. Kaze et al. Diabetes Care 2024;47(8):1408–1414. https://doi.org/10.2337/dc24-0294.
Association of Metabolic Syndrome With Neuroimaging and Cognitive Outcomes in the UK Biobank. Qureshi et al. Diabetes Care 2024;47(8):1415–1423. https://doi.org/10.2337/dc24-0537.
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. Malhotra et al. N Engl J Med 2024;June 21. Epub ahead of print. DOI: 10.1056/NEJMoa2404881.
Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT. Lingvay et al. Diabetes Care 2024;47(8):1360–1369. https://doi.org/10.2337/dc24-0764.
June 28, 2024
Diabetes Core Update July 2024
Play Episode
Total Time: 37:54 | File Size: 52 MB
Sources
Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists. Emanuel et al. N Engl J Med 2024;390(20):1839-1842. https://doi.org/10.1056/nejmp2400978.
Medical Assistant Health Coaching for Type 2 Diabetes in Primary Care: Results From a Pragmatic Cluster Randomized Controlled Trial. Fortmann et al. Diabetes Care 2024;47(7):1171-1180. https://doi.org/10.2337/dc23-2487.
Glycemic Control, Cognitive Aging, and Impairment Among Diverse Hispanic/Latino Individuals: Study of Latinos- Investigation of Neurocognitive Aging (Hispanic Community Health Study/Study of Latinos). González et al. Diabetes Care 2024;47(7):1152-1161. https://doi.org/10.2337/dc23-2003.
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. Loomb et al. N Engl J Med 2024;Jun 8. doi: 10.1056/NEJMoa2401943. Epub ahead of print. https://doi.org/10.1056/nejmoa2401943.
Is Weight Loss-Induced Muscle Mass Loss Clinically Relevant? Conte et al. JAMA 2024;Jun 3. doi: 10.1001/jama.2024.6586. Epub ahead of print. https://doi.org/10.1001/jama.2024.6586.
June 7, 2024
Diabetes Core Update June 2024
Play Episode
Total Time: 54:00 | File Size: 75 MB
Sources
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. Kosiborod et al. N Engl J Med 2024;390(15):1394–1407. https://doi.org/10.1056/nejmoa2313917.
Habitual Short Sleep Duration, Diet, and Development of Type 2 Diabetes in Adults. Nôga et al. JAMA Netw Open 2024;7(3):e241147. https://doi.org/10.1001/jamanetworkopen.2024.1147.
Effects of Tirzepatide Versus Basal Insulins in People With Type 2 Diabetes and Different Baseline Glycemic Patterns: Post Hoc Analyses of the SURPASS-3 and SURPASS-4 Trials. Giorgino et al. Diabetes Care 2024;47(6):1020–1027. https://doi.org/10.2337/dc23-2366.
Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program. Zeitler et al. Diabetes Care 2024;47(6):1056–1064. https://doi.org/10.2337/dc23-2356.
Cardiovascular and mortality benefits of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists as third-step glucose-lowering medicine in patients with type 2 diabetes: a retrospective cohort analysis. McCormick et al. BMJ Open Diabetes Res Care 2024;12(3):e003792. https://doi.org/10.1136/bmjdrc-2023-003792.
Association of Continued Use of SGLT2 Inhibitors From the Ambulatory to Inpatient Setting With Hospital Outcomes in Patients With Diabetes: A Nationwide Cohort Study. Singh et al. Diabetes Care 2024;47(6):933–940. https://doi.org/10.2337/dc23-1129.
May 4, 2024
Play Episode
Total Time: 25:33 | File Size: 35 MB
Sources
Loneliness and the risk of type 2 diabetes. Rosenkilde et al. BMJ Open Diabetes Res Care 2024;12(2):e003934. https://doi.org/10.1136/bmjdrc-2023-003934.
Microplastics and Nanoplastics in Atheromas and Cardiovascular Events. Marfella et al. N Engl J Med 2024;390(10):900–910. https://doi.org/10.1056/nejmoa2309822.
Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS-AP-Combo. Ma et al. Obes Metab 2024;26(4):1454–1463. https://doi.org/10.1111/dom.15446.
Comparing Continuous Glucose Monitoring and Blood Glucose Monitoring in Adults With Inadequately Controlled, Insulin-Treated Type 2 Diabetes (Steno2tech Study): A 12-Month, Single-Center, Randomized Controlled Trial. Lind et al. Diabetes Care 2024;47(5):881–889. https://doi.org/10.2337/dc23-2194.
Influence of a diet and/or exercise intervention on long-term mortality and vascular complications in people with impaired glucose tolerance: Da Qing Diabetes Prevention Outcome study. Yu et al. Diabetes Obes Metab 2024;26(4):1188-1196. https://doi.org/10.1111/dom.15413.
Timing of Moderate to Vigorous Physical Activity, Mortality, Cardiovascular Disease, and Microvascular Disease in Adults With Obesity. Sabag et al. Diabetes Care 2024;47(5):890–897. https://doi.org/10.2337/dc23-2448.
April 2, 2024
Diabetes Core Update April 2024
Play Episode
Total Time: 53:52 | File Size: 74 MB
Sources
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. Harrison et al. N Engl J Med 2024;390(6):497–509. https://www.nejm.org/doi/10.1056/NEJMoa2309000.
Long-Term Outcomes of Medical Management vs Bariatric Surgery in Type 2 Diabetes. Courcoulas et al. JAMA 2024;331(8):654–664. https://doi.org/10.1001/jama.2024.0318.
Improved Glycemic Outcomes With Diabetes Technology Use Independent of Socioeconomic Status in Youth With Type 1 Diabetes. Lomax et al. Diabetes Care 2024;47(4):707–711. https://doi.org/10.2337/dc23-2033.
Cardiovascular and Kidney Risks in Individuals With Type 2 Diabetes: Contemporary Understanding With Greater Emphasis on Excess Adiposity. Sattar et al. Diabetes Care 2024;47(4):531–543. https://doi.org/10.2337/dci23-0041.
Epidemiology and Prognostic Implications of Coronary Artery Calcium in Asymptomatic Individuals With Prediabetes: A Multicohort Study. Al Rifai et al. Diabetes Care 2024;47(4):698–706. https://doi.org/10.2337/dc23-1864.
February 27, 2024
Diabetes Core Update March 2024
Play Episode
Total Time: 24:05 | File Size: 33 MB
Sources
Leisure-Time Physical Activity May Attenuate the Impact of Diabetes on Cognitive Decline in Middle-Aged and Older Adults: Findings From the ELSA-Brasil Study. Feter et al. Diabetes Care 2024;47(3):427–434. https://doi.org/10.2337/dc23-1524.
Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status. Bea et al. JAMA Netw Open 2024;6(12):e2349856. https://doi.org/10.1001/jamanetworkopen.2023.49856.
Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes. Paik et al. JAMA Intern Med 2024; Epub ahead of print Jan 29:e237660. https://doi.org/10.1001/jamainternmed.2023.7660.
Association of Body Weight Time in Target Range With the Risk of Kidney Outcomes in Patients With Overweight/Obesity and Type 2 Diabetes Mellitus. Zu et al. Diabetes Care 2024;47(3):371–378. https://doi.org/10.2337/dc23-1727.
Modifiable Lifestyle Factors, Genetic Risk, and Incident Peripheral Artery Disease Among Individuals With Type 2 Diabetes: A Prospective Study. Zhu et al. Diabetes Care 2024;2024;47(3):435–443. https://doi.org/10.2337/dc23-1503.
January 24, 2024
Diabetes Core Update February 2024
Play Episode
Total Time: 33:28 | File Size: 46 MB
Sources
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. Aronne et al. JAMA 2024;331(1):38–48. https://doi.org/10.1001/jama.2023.24945.
Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6. Klein et al. Diabetes Care;2024;47(2):280–284. https://doi.org/10.2337/dc23-1791.
Diagnostic yield of a proactive strategy for early detection of cardiovascular disease versus usual care in adults with type 2 diabetes or chronic obstructive pulmonary disease in primary care in the Netherlands (RED-CVD): a multicentre, pragmatic, cluster-randomised, controlled trial. Groenewegen et al. Lancet Public Health 2023; Epub ahead of print December 19, 2023. https://doi.org/10.1016/S2468-2667(23)00269-4.
Low-Dose Antithymocyte Globulin: A Pragmatic Approach to Treating Stage 2 Type 1 Diabetes. Foster et al. Diabetes Care 2024;47(2):285–289. https://doi.org/10.2337/dc23-1750.
Assessment of Glycemic Control by Continuous Glucose Monitoring, Hemoglobin A1c, Fructosamine, and Glycated Albumin in Patients With End-Stage Kidney Disease and Burnt-Out Diabetes. Kaminski et al. Diabetes Care 2024;47(2):267–271. https://doi.org/10.2337/dc23-1276.
December 27, 2023
Diabetes Core Update January 2024
Play Episode
Total Time: 35:10 | File Size: 49 MB
Sources
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. Lincoff et al. N Engl J Med 2023;389(24):2221–2232. https://doi.org/10.1056/nejmoa2307563.
Economic Costs of Diabetes in the U.S. in 2022. Parker et al. Diabetes Care 2023;47(1):26–43. https://doi.org/10.2337/dci23-0085.
Intensive Lifestyle Intervention for Remission of Early Type 2 Diabetes in Primary Care in Australia: DiRECT-Aus. Hocking et al. Diabetes Care 2023;47(1):66–70. https://doi.org/10.2337/dc23-0781.
Efficacy and Safety of Continuous Glucose Monitoring and Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Interventional Evidence. Seidu et al. Diabetes Care 2023;47(1):169–179. https://doi.org/10.2337/dc23-1520.
Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Ndumele et al. Circulation 2023;148(20):1606–1635. https://doi.org/10.1161/cir.0000000000001184.
